scout

All News

Analyses from the phase III ALSYMPCA trial showed that treatment with radium-223 resulted in quality-of-life improvements over placebo in patients with castration-resistant prostate cancer and symptomatic bone metastases.

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.

How arduous is it to transform a typical practice into a community oncology medical home? Let’s compare the characteristics of the ideal community oncology medical home as defined by Innovative Oncology Business Solutions with our practice’s current habits.